Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies

Immunology

Volumn 108, Issue 3, 2003, Pages 409-419

  Winter, Hauke ^a,g   Hu, Hong Ming ^a,b   Poehlein, Christian H ^a   Huntzicker, Erik ^a   Osterholzer, John J ^a   Bashy, Jaffar ^a,d   Lashley, David ^a,d   Lowe, Bruce ^d   Yamada, Jane ^a   Alvord, Gregory ^e   Urba, Walter J ^a   Fox, Bernard A ^a,b,c,f  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Oregon Acupuncture Center   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f EARLE A CHILES RESEARCH INSTITUTE   (United States)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; L SELECTIN; TUMOR VACCINE;

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPH NODE CELL; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR; TUMOR IMMUNOLOGY; TUMOR REGRESSION; TUMOR REJECTION; VACCINATION;

ANIMALS; CANCER VACCINES; CYTOKINES; FEMALE; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037341335     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01596.x     Document Type: Article

References (54)

1. Hu HM, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998; 161:3033-41.
2. Rocken M, Shevach EM. Immune deviation - the third dimension of nondeletional T cell tolerance. Immunol Rev 1996; 149:175-94.
3. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more [see comments]. Immunol Today 1996; 17:138-43.
4. Li L, Sad S, Kagi D, Mosmann TR. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J Immunol 1997; 158:4152-61.
5. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL) -4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994; 180:1715-28.
6. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254:279-82.
7. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunology 1994; 12:635-73.
8. Gollob JA, Kawasaki H, Ritz J. Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur J Immunol 1997; 27:647-52.
9. Nakamura T, Lee RK, Nam SY, Podack ER, Bottomly K, Flavell RA. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol 1997; 158:2648-53.
10. Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Type 1 vs Type 2 cytokine release by Vb T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 1997; 159:664-73.
11. Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE. Therapeutic efficacy oft cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 1996; 3:39-44.
12. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. Cancer 1993; 71:1165-71.
13. Shu SY, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 1989; 143:740-8.
14. Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 1994; 152:1277-88.
15. Yoshizawa H, Sakai K, Chang AE, et al. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 1991; 134:473-9.
16. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000; 290:1354-7.
17. Hellstrom KE, Hellstrom I, Chen L, Ashe S, Brady WA, Ledbetter JA, McGowan P, Linsley PS. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 1995; 145:123-41.
18. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in. Cell 1992; 71:1065-8.
19. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71:1093-102.
20. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells [see comments]. Science 1993; 259:368-70.
21. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045.
22. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms. Adv Immunol 2000; 74:181-95.
23. Trowsdale J, Travers P, Bodmer WF, Patillo RA. Expression of HLA-A-B, and -C and beta 2-microglobulin antigens in human. J Exp Med 1980; 152:11s-7s.
24. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177:265-72.
25. Ochsenbein AF, Pinschewer DD, Sierro S, Horvath E, Hengartner H, Zinkernagel RM. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci USA 2000; 97:13263-8.
26. Asherson GL, Stone SH. Selective and specific inhibition of 24 hour skin reactions in the guinea-pig. I. Immune deviation: description of the phenomenon and the effect of splenectomy. Immunology 1965; 9:205-17.
27. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-57.
28. Tamada K, Harada M, Abe K, Li T. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes. J Immunol 1997; 158:4846-54.
29. Inoue M, Minami M, Fujii Y, Matsuda H, Shirakura R. Granulocyte colony-stimulating factor and interleukin-6-producing lung cancer cell line, LCAM. J Surg Oncol 1997; 64:347-50.
30. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL) -6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997; 185:461-9.
31. Bendelac A, Rivera MN, Park S-H, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15:535-62.
32. von der Weid T, Beebe AM, Roopenian DC, Coffman RL. Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1-T cell population. J Immunol 1996; 157:4421-7.
33. Constant SL, Bottomly K. Induction of Th1 and Th2, CD4+ T cell responses: alternative approaches. Annu Rev Immunol 1997; 15:297-322.
34. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 1995; 182:1579-84.
35. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2:947-50.
36. Vremec D, Zorbas M, Scollay R, Saunders DJ, Ardavin CF, Wu L, Shortman K. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med 1992; 176:47-58.
37. Maldonado-Lopez R, De Smedt T et al. CD8alpha+ and CD8alphasubclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587-92.
38. Maldonado-Lopez R, De Smedt T, Pajak B et al. Role of CD8alpha+ and CD8alpha- dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol 1999; 66:242-6.
39. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45:322-33.
40. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8:579-621.
41. Davies JD, Martin G, Phillips J, Marshall SE. Cobbold SP, Waldmann H. T cell regulation in adult transplantation tolerance. J Immunol 1996; 157:529-33.
42. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance [published erratum appears in Nature 1995 Sep 21; 377 (6546):257]. Nature 1995; 376:177-9.
43. Maeda H, Takata M, Takahashi S, Ogoshi S, Fujimoto S. Adoptive transfer of a Th2-like cell line prolongs MHC class II antigen disparate skin allograft survival in the mouse. Int Immunol 1994; 6:855-62.
44. Plain KM, Fava L, Spinelli A, He XY, Chen J, Boyd R, Davidson CL, Hall BM. Induction of tolerance with nondepleting anti-CD4 monoclonal antibodies is associated with down-regulation of TH2 cytokines. Transplantation 1997; 64:1559-67.
45. Winter H, Hu HM, McClain K, Urba WJ, Fox BA. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol 2001; 166:7370-80.
46. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD 2001 IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature; 410:1107-11.
47. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system. Proc Natl Acad Sci USA 1998; 95:7556-61.
48. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1:447-56.
49. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749-95.
50. Dobrzanski MJ, Reome JB, Dutton RW. Immunopotentiating role of IFN-gamma in early and late stages of type 1, CD8 effector cell-mediated tumor rejection. Clin Immunol 2001; 98:70-84.
51. Hu H-M, Poehlein CH, Urba WJ, Fox BA. Development of anti-tumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002; 62:3914-9.
52. Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM. Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002; 168:338-47.
53. Meijer SL, Dols A, Urba WJ et al. Adoptive cellular therapy with tumor vaccine-draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother 2002; 25:359-72.
54. Tatsumi T, Kierstead LS, Ranieri E et al. Disease-associated bias in T helper type 1 (Th1)/Th2, CD4(+) T cell responses against MAGE-6 in HLA-DRB 10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196:619-28.